Cryo-Cell International Q2 2024 GAAP EPS $0.08 Beats $0.04 Estimate
Portfolio Pulse from Benzinga Newsdesk
Cryo-Cell International (NASDAQ:CCEL) reported Q2 2024 GAAP EPS of $0.08, beating the analyst consensus estimate of $0.04 by 100%. This represents a 166.67% increase over the same period last year.
July 15, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cryo-Cell International reported Q2 2024 GAAP EPS of $0.08, beating the analyst consensus estimate of $0.04 by 100%. This is a significant improvement from the $0.03 EPS reported in the same period last year, indicating strong financial performance.
The significant beat on earnings estimates and the substantial year-over-year increase in EPS are likely to positively impact CCEL's stock price in the short term. Investors will view this as a sign of strong financial health and growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100